Literature DB >> 7575223

A standardized technique for establishing onset and duration of symptoms of Alzheimer's disease.

M Sano1, D P Devanand, M Richards, L W Miller, K Marder, K Bell, G Dooneief, F W Bylsma, G Lafleche, M Albert.   

Abstract

OBJECTIVES: To develop an informant-based semistructured interview to determine the onset and duration of symptoms of Alzheimer's disease, and to use this instrument with informants to characterize a cohort of mildly impaired patients with Alzheimer's disease.
DESIGN: In study 1, interrater and interinformant reliability was examined for the date of onset and the order of appearance for specific symptoms that were elicited by the semistructured onset interview. In study 2, the instrument was used to characterize disease onset in a cohort of patients with Alzheimer's disease who were participating in a large multicenter study.
SUBJECTS: Informants of patients with Alzheimer's disease.
RESULTS: In study 1, interrater reliability for duration of illness was excellent (intraclass correlation coefficient = .99, P < .001), and interinformant reliability was good (intraclass correlation coefficient = .86, P < .001). Agreement for the presence of a given symptom was highest for those that were most commonly reported (eg, memory and performance difficulty). In study 2, 89% of the cohort had memory problems, and 63.9% had performance difficulties as the first or second symptom. Depression and language problems were less commonly reported. Psychosis and behavioral disturbances were rarely reported as the first problem.
CONCLUSION: This instrument provides a reliable procedure for standardizing the estimation of duration of illness based on retrospective report.

Entities:  

Mesh:

Year:  1995        PMID: 7575223     DOI: 10.1001/archneur.1995.00540340045012

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  6 in total

1.  Differentiated clinical presentation of early and late-onset Alzheimer's disease: is 65 years of age providing a reliable threshold?

Authors:  Antonio Palasí; Belén Gutiérrez-Iglesias; Montse Alegret; Francesc Pujadas; Mikel Olabarrieta; Diana Liébana; Manolo Quintana; José Álvarez-Sabín; Mercè Boada
Journal:  J Neurol       Date:  2015-03-21       Impact factor: 4.849

2.  Factors associated with psychotic symptoms in Alzheimer's disease.

Authors:  N Hirono; E Mori; M Yasuda; Y Ikejiri; T Imamura; T Shimomura; M Ikeda; M Hashimoto; H Yamashita
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

3.  Predictive utility of type and duration of symptoms at initial presentation in patients with mild cognitive impairment.

Authors:  Deidre J Devier; Nicole Villemarette-Pittman; Patrick Brown; Gregory Pelton; Yaakov Stern; Mary Sano; D P Devanand
Journal:  Dement Geriatr Cogn Disord       Date:  2010-09-15       Impact factor: 2.959

4.  Eye-Tracking Metrics for Figure-Copying Processes in Early- vs. Late-Onset Alzheimer's Disease.

Authors:  Ko Woon Kim; Jongdoo Choi; Juhee Chin; Byung Hwa Lee; Duk L Na
Journal:  Front Neurol       Date:  2022-05-16       Impact factor: 4.086

5.  Differences between Early and Late-Onset Alzheimer's Disease in Neuropsychological Tests.

Authors:  Francisca Sá; Paula Pinto; Catarina Cunha; Raquel Lemos; Liliana Letra; Mário Simões; Isabel Santana
Journal:  Front Neurol       Date:  2012-05-14       Impact factor: 4.003

6.  CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer's disease.

Authors:  Giacomo Koch; Francesco Di Lorenzo; Stefano Loizzo; Caterina Motta; Sara Travaglione; Monica Baiula; Roberto Rimondini; Viviana Ponzo; Sonia Bonnì; Sofia Toniolo; Fabrizio Sallustio; Marco Bozzali; Carlo Caltagirone; Gabriele Campana; Alessandro Martorana
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.